AMA1-RON2 Complex-Based Vaccine Against Malaria

This technology relates to a malaria vaccine composed of a protein complex of Apical Membrane Antigen (AMA1) and rhoptry neck protein 2 (RON2) with an adjuvant. AMA1 is a crucial component of the Plasmodium invasion machinery and is a leading candidate for antimalarial vaccine development. AMA1-based vaccines have shown ability to block red cell invasion in in vitro assays, but protection has so far not translated to in vivo human infections. NIAID investigators have demonstrated that interaction between AMA1 and RON2 (or peptide thereof) is essential for malaria parasites to successfully enter human red blood cells (RBCs). Vaccination with un-complexed AMA1 and RON2 did not protect against lethal malaria. However, vaccination with a pre-formed AMA1-RON2 complex, highlighted in this technology, produced antibodies that protected against lethal malaria in an in vivo mouse model (P. yoelli) and blocked the entry of human malaria parasites into RBCs in vitro. Additionally, the inhibitory antibody response induced by the AMA1-RON2 complex was greater than AMA1 alone or when AMA1 and RON2 proteins were administered in a un-complexed form.

Immunization using the AMA1-RON2 complex of this technology represents a candidate for an effective malaria vaccine against multiple Plasmodium species.

Potential Commercial Applications: Competitive Advantages:
  • Malaria vaccine
  • Lower-cost malarial prevention for developing/developed countries

Development Stage:
  • Early-stage
  • In vitro data available
  • In vivo data available (animal)


Prakash Srinivasan (NIAID)  ➽ more inventions...

Louis Miller (NIAID)  ➽ more inventions...

Intellectual Property:
U.S. Pat: 9,795,662 issued 2017-10-24
US Application No. 61/841,479
PCT Application No. PCT/US2014/045065
Various international patent applications may also be available.

Srinivasan P, et al. PMID 21788485
Srinivasan P, et al. PMID 23907321

Collaboration Opportunity:

The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize MA1-RON2 vaccine by providing well established human adjuvants and clinical trial funding. For collaboration opportunities, please contact Peter Tung, Ph.D. at 240-669-5483 or

Licensing Contact:
Peter Tung, Ph.D., M.B.A.
Phone: 240-669-5483

OTT Reference No: E-066-2013-0
Updated: Mar 9, 2017